Back to All

Laboratory Turnaround Time for FLT3 testing in relapsed acute myeloid leukemia needs improvement

13 June, 2019

Researchers at Diaceutics uncovered the need for faster laboratory testing turnaround times (TAT) in an abstract accepted for publication by the European Hematology Association (EHA) for its annual meeting in June 2019. The abstract, entitled “FLT3 Testing in Relapsed Acute Myeloid Leukemia Setting Is Becoming Increasingly Common, But Laboratory Turnaround Times (TAT) May Be a Barrier to Treatment With Second Generation FLT3 Inhibitors,” analyzed the FLT3 testing behavior in relapsed acute myeloid leukemia (AML) over the course of a year. 

The researchers discovered an increase in awareness of the need for retesting in FLT3 and the need for faster TAT in the relapsed setting. However, the TAT results did not demonstrate an improvement in actual TAT, with the average TAT remaining suboptimal at 12.6 days.This may be due to the lack of an approved FLT3 inhibitor for second-line treatment in Europe. Lab TAT will be a key metric to monitor over the coming 12 to 18 months. 

For more information on these findings, contact [email protected]. 

Read Full Abstract here. 

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.